Abstract
Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | European Journal of Internal Medicine |
| Jahrgang | 26 |
| Ausgabenummer | 7 |
| Seiten (von - bis) | 545-553 |
| Seitenumfang | 9 |
| ISSN | 0953-6205 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.09.2015 |
Fördermittel
David Jayne: research grants from Genzyme and Roche/Genentech; consultancy for Aurinia, Biogen, Chemocentryx, GSK, Lilly and Medimmune, Merck Serono and Roche/Genentech. Peter Merkel: research grants from Bristol-Myers Squibb, Celgene, Genentech/Roche and GSK; consulting fees from Actelion, GSK and Sanofi. Loïc Guillevin: Member of the Advisory Board that designed an EGPA mepolizumab trial; member of the Scientific Council of the AIR registry, funded by Roche Laboratory; lecture fees paid by LFB, Roche Pharma and CSL Behring; Roche Laboratory partially provided rituximab for the MAINRITSAN trial (National PHRC No. 2008-002846-51) comparing rituximab vs. azathioprine as maintenance therapy for ANCA-associated vasculitides.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver